IMPORTANT MESSAGE
Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Clinical Supply Chain Management: Biotech – Phase III Study
Clinical Supply Chain Management: Biotech – Phase III Study
Rapid Response and Flexibility Ensures Continual Drug Supply.
A small, US-based biotech company was planning a 5 year, phase III, randomised, double-blinded, placebo-controlled study. The study was conducted across multiple sites in the US involving 10,600 patients.This was a pivotal study for the client who initially contacted Almac for a better understanding of clinical trial supply management and to leverage our expertise to determine how much drug they would require.
Following discussions with our Supply Chain Management (SCM) team, they felt they lacked the resources and expertise internally and contracted Almac to provide core supply chain management services.The Almac SCM team assisted with devising optimal and cost effective packaging, distribution and drug accountability strategies throughout the life of the study.
